MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on November 30, 2007; DOI: 10.1124/mol.107.042002


0026-895X/08/7303-709-717$20.00
Mol Pharmacol 73:709-717, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.107.042002v1
73/3/709    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Bren-Mattison, Y.
Right arrow Articles by Nemenoff, R. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bren-Mattison, Y.
Right arrow Articles by Nemenoff, R. A.

Antitumorigenic Effects of Peroxisome Proliferator-Activated Receptor-{gamma} in Non-Small-Cell Lung Cancer Cells Are Mediated by Suppression of Cyclooxygenase-2 via Inhibition of Nuclear Factor-{kappa}BFormula

Yvette Bren-Mattison1, Amy M. Meyer, Vicki Van Putten, Howard Li, Katherine Kuhn, Robert Stearman, Mary Weiser-Evans, Robert A. Winn, Lynn E. Heasley, and Raphael A. Nemenoff

Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado

Pharmacological activators of peroxisome proliferator-activated receptor-{gamma} (PPAR{gamma}) inhibit growth of non-small-cell lung cancer (NSCLC) cell lines in vitro and in xenograft models. Because these agents engage off-target pathways, we have assessed the effects of PPAR{gamma} by overexpressing the protein in NSCLC cells. We reported previously that increased PPAR{gamma} inhibits transformed growth and invasiveness and promotes epithelial differentiation in a panel of NSCLC expressing oncogenic K-Ras. These cells express high levels of cyclooxygenase-2 (COX-2) and produce high levels of prostaglandin E2 (PGE2). The goal of these studies was to identify the molecular mechanisms whereby PPAR{gamma} inhibits tumorigenesis. Increased PPAR{gamma} inhibited expression of COX-2 protein and promoter activity, resulting in decreased PGE2 production. Suppression of COX-2 was mediated through increased activity of the tumor suppressor phosphatase and tensin homolog, leading to decreased levels of phospho-Akt and inhibition of nuclear factor-{kappa}B activity. Pharmacological inhibition of PGE2 production mimicked the effects of PPAR{gamma} on epithelial differentiation in three-dimensional culture, and exogenous PGE2 reversed the effects of increased PPAR{gamma} activity. Transgenic mice overexpressing PPAR{gamma} under the control of the surfactant protein C promoter had reduced expression of COX-2 in type II cells and were protected against developing lung tumors in a chemical carcinogenesis model. These data indicate that high levels of PGE2 as a result of elevated COX-2 expression are critical for promoting lung tumorigenesis and that the antitumorigenic effects of PPAR{gamma} are mediated in part through blocking this pathway.


Received September 19, 2007; accepted November 30, 2007

Address correspondence to: Dr. Raphael Nemenoff, Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Health Sciences Center, Box C-281, 4200 East 9th Avenue, Denver, CO 80262. E-mail: raphael.nemenoff{at}uchsc.edu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics